These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20817887)

  • 41. A robust high-throughput sandwich cell-based drug screening platform.
    Zhang S; Tong W; Zheng B; Susanto TA; Xia L; Zhang C; Ananthanarayanan A; Tuo X; Sakban RB; Jia R; Iliescu C; Chai KH; McMillian M; Shen S; Leo H; Yu H
    Biomaterials; 2011 Feb; 32(4):1229-41. PubMed ID: 20971505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incorporating the empirical null hypothesis into the Benjamini-Hochberg procedure.
    Ghosh D
    Stat Appl Genet Mol Biol; 2012 Jul; 11(4):. PubMed ID: 22850065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Luciferase Advisor: High-Accuracy Model To Flag False Positive Hits in Luciferase HTS Assays.
    Ghosh D; Koch U; Hadian K; Sattler M; Tetko IV
    J Chem Inf Model; 2018 May; 58(5):933-942. PubMed ID: 29667823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mass spectrometric techniques for label-free high-throughput screening in drug discovery.
    Roddy TP; Horvath CR; Stout SJ; Kenney KL; Ho PI; Zhang JH; Vickers C; Kaushik V; Hubbard B; Wang YK
    Anal Chem; 2007 Nov; 79(21):8207-13. PubMed ID: 17902631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-throughput assessment of antigen conformational stability by ultraviolet absorption spectroscopy and its application to excipient screening.
    Dasnoy S; Le Bras V; Préat V; Lemoine D
    Biotechnol Bioeng; 2012 Feb; 109(2):502-16. PubMed ID: 21928339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PowerMV: a software environment for molecular viewing, descriptor generation, data analysis and hit evaluation.
    Liu K; Feng J; Young SS
    J Chem Inf Model; 2005; 45(2):515-22. PubMed ID: 15807517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Compound set enrichment: a novel approach to analysis of primary HTS data.
    Varin T; Gubler H; Parker CN; Zhang JH; Raman P; Ertl P; Schuffenhauer A
    J Chem Inf Model; 2010 Dec; 50(12):2067-78. PubMed ID: 21073183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications.
    Dejaegher B; Heyden YV
    J Pharm Biomed Anal; 2011 Sep; 56(2):141-58. PubMed ID: 21632194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data.
    Mpindi JP; Swapnil P; Dmitrii B; Jani S; Saeed K; Wennerberg K; Aittokallio T; Östling P; Kallioniemi O
    Bioinformatics; 2015 Dec; 31(23):3815-21. PubMed ID: 26254433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-throughput assays for promiscuous inhibitors.
    Feng BY; Shelat A; Doman TN; Guy RK; Shoichet BK
    Nat Chem Biol; 2005 Aug; 1(3):146-8. PubMed ID: 16408018
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statistics and decision making in high-throughput screening.
    Coma I; Herranz J; Martin J
    Methods Mol Biol; 2009; 565():69-106. PubMed ID: 19551358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On the use of historical control data in pre-clinical safety studies.
    Marringwa JT; Faes C; Aerts M; Geys H; Teuns G; Van Den Poel B; Bijnens L
    J Biopharm Stat; 2007; 17(3):493-509. PubMed ID: 17479396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
    Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M
    J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coping with complexity: machine learning optimization of cell-free protein synthesis.
    Caschera F; Bedau MA; Buchanan A; Cawse J; de Lucrezia D; Gazzola G; Hanczyc MM; Packard NH
    Biotechnol Bioeng; 2011 Sep; 108(9):2218-28. PubMed ID: 21520017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HTS promiscuity analyses for accelerating decision making.
    Böcker A; Bonneau PR; Edwards PJ
    J Biomol Screen; 2011 Aug; 16(7):765-74. PubMed ID: 21680863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of mixture distributions to deconvolute the behavior of "hits" and controls in high-throughput screening data.
    Buxser S; Chapman DL
    Anal Biochem; 2007 Feb; 361(2):197-209. PubMed ID: 17214952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
    Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
    Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benchmarking of multivariate similarity measures for high-content screening fingerprints in phenotypic drug discovery.
    Reisen F; Zhang X; Gabriel D; Selzer P
    J Biomol Screen; 2013 Dec; 18(10):1284-97. PubMed ID: 24045583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Framework for the rapid optimization of soluble protein expression in Escherichia coli combining microscale experiments and statistical experimental design.
    Islam RS; Tisi D; Levy MS; Lye GJ
    Biotechnol Prog; 2007; 23(4):785-93. PubMed ID: 17592858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Uniformity trials in plant freezing assays involving microtitre plates.
    Zaragotas D; Anastassopoulos E
    Cryo Letters; 2011; 32(1):21-7. PubMed ID: 21468450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.